The brain and nervous system play an important role in pancreatic β-cell function. This study investigated the role of muscarinic agonists or acetylcholine, which is the major neurotransmitter in the vagal nerve, in regulating pancreatic β-cell mass and glucose homeostasis. Administration of the muscarinic agonist bethanechol increased insulin secretion and improved glucose tolerance in insulinreceptor substrate 2 (IRS2)-knockout (IRS-2 −/− ) mice and diet-induced obesity mice. Oral administration of bethanechol increased β-cell mass and proliferation in wild-type mice, but not IRS-2 −/− mice. The muscarinic agonist also increased the incorporation of 5-bromo-2′-deoxyuridine (BrdU) into islets isolated from wild-type mice and pancreatic β-cell line MIN6. The phosphorylation of protein kinase B (Akt) induced by oral administration of bethanechol was observed in wild-type mice, but not IRS-2 −/− mice. The secretion of glucagon-like peptide-1 (GLP-1) was also stimulated by bethanechol in wild-type mice, and a GLP-1 antagonist partially inhibited the bethanechol-induced increase in β-cell mass. These results suggest that the muscarinic agonist exerted direct and indirect effects on β-cell proliferation that were dependent on the IRS-2/Akt pathway. The bethanechol-stimulated release of GLP-1 may be indirectly associated with β-cell proliferation.
Results
Administration of muscarinic agonist bethanechol improves glucose homeostasis in diabetic model mice and diet-induced obesity mice. To examine the effect of bethanechol in a mouse model of diabetes, it was administered to IRS-2 −/− mice, which show insulin resistance and high glucose levels. Bethanechol (2 µg/g) was injected subcutaneously 15 min prior to oral glucose loading in wild-type mice and IRS-2 −/− mice. Bethanechol increased insulin secretion and improved glucose tolerance in both types of mice (Fig. 1A) . The bethanechol-induced secretion of insulin in the IRS-2 −/− mice was higher than that in the wildtype mice (Fig. 1B) . The results of the insulin tolerance test revealed no significant difference in glucose levels between the control and bethanechol groups of wild-type mice; however, 30 min following insulin injection, the glucose level in the bethanechol-injected IRS-2 −/− mice was significantly lower than that in the control mice (Fig. 1C) .
To examine the effect of bethanechol on diet-induced obesity (DIO) mice, 7-week-old male mice were fed a high-fat diet (HFD) for 5-6 or 16 weeks, following which an oral glucose tolerance test was performed. The subcutaneous administration of bethanechol (5 µg/g) prior to oral glucose loading improved glucose tolerance ( Fig. 2A,C) and increased insulin secretion markedly (Fig. 2B,D) . Oral administration of bethanechol (100 µg/g) also improved casual glucose after 1 and 2 h of administration ( Fig. 2E) , and increased insulin secretion significantly after 1 h in DIO mice (Fig. 2F ).
Bethanechol administration caused cholinergic side effects in DIO mice and wild-type (WT) mice. The number of mice exhibiting salivation or lacrimation was counted. Subcutaneous administration of bethanechol (5 µg/g) in the mice fed a HFD for 5-6 or 16 weeks, respectively, induced salivation (41.6% and 100%) and lacrimation (25% and 33.3%) ( Supplementary Table) . In the mice administered oral bethanechol (100 µg/g), no salivation or lacrimation were observed. Bethanechol (5 µg/g) administered subcutaneously also caused miosis in WT mice (slight contraction from 4 mm to 3-3.5 mm), as measured macroscopically with a loupe (data not shown).
Chronic administration of bethanechol promotes β-cell proliferation. Long-term administration of bethanechol in mice was examined by measuring blood glucose levels and changes in body weight. Bethanechol was added to drinking water at a concentration of 30 µg/mL, and the casual blood glucose and body weight were measured for 20 weeks in WT and IRS-2 −/− mice. There were no significant differences in body weight, casual blood glucose or glucose tolerance between mice with or without bethanechol administration, in both WT and the IRS-2 −/− mice (Figs 3A,B; S1). The β-cell mass of mice continuously administered bethanechol (30 µg/mL in water) was also evaluated for 6 weeks. In the WT mice, the β-cell mass increased significantly in those receiving bethanechol compared with the controls (control: 0.76 mg; bethanechol: 1.08 mg). However, there was no significant difference in the β-cell mass between the bethanechol-administered IRS-2 −/− mice and control IRS-2 −/− mice (control: 0.70 mg; bethanechol: 0.84 mg; Fig. 3C ).
The incorporation of 5-bromo-2′-deoxyuridine (BrdU) was assessed to determine the effect of the muscarinic agonist on the proliferation of β-cells. As shown in Fig. 3D , bethanechol (30 µg/mL in water) administration increased the number of BrdU-positive cells (control: 0.63%; bethanechol: 1.29%) in the WT mice. In the IRS-2 −/− mice, no significant increase in BrdU-positive cells was observed following agonist administration (control: 0.81%; bethanechol: 0.94%; Fig. 3D ).
To examine the issue of bethanechol stability in water, bethanechol was given orally at 1 µg/g body weight once a day, and the β-cell mass was measured 2 weeks following the start of administration (Fig. 3E ). The WT mice that were treated with bethanechol exhibited an increase in the β-cell mass compared with control mice (control: 1.05 mg; bethanechol: 1.55 mg), whereas no significant increase was observed in the IRS-2 −/− mice (control: 1.03 mg; bethanechol: 0.82 mg).
Bethanechol directly stimulates pancreatic β-cell proliferation.
To determine whether bethanechol has a direct effect on pancreatic β cells, BrdU incorporation was investigated in the pancreatic β-cell line MIN6. MIN6 cells were cultured in media containing BrdU and the muscarinic agonist for 24 h, following which the cells were fixed, stained with fluorescent isothiocyanate (FITC)-labelled BrdU antibodies and analysed by flow cytometry. BrdU incorporation increased significantly in the carbachol-treated or bethanechol-treated cells in a concentration-dependent manner (Fig. 4A,B ). This increase was suppressed completely by the addition of atropine 50 µM (Fig. 4C ). The Akt inhibitor perifosine (5 µM) inhibited the bethanechol (1 mM)-induced incorporation of BrdU ( Fig. 4D ), whereas the mitogen-activated protein kinase (MEK) inhibitor PD98059 (50 µM) did not ( Fig. 4E ).
Islets were isolated from 8-week-old WT or IRS-2 −/− mice to examine the incorporation of BrdU following treatment with muscarinic agonists in a similar manner. Islets were incubated in media containing bethanechol (1 mM) or carbachol (0.5 mM) and BrdU for 24 h, after which BrdU incorporation was measured. Similar to that in MIN6 cells, a significant increase in BrdU incorporation was observed following the stimulation of islets from WT mice with bethanechol (1 mM) or carbachol (0.5 mM) ( Fig. 4F ). In islets from the IRS-2 −/− mice, no BrdU incorporation was observed ( Fig. 4F ). Collectively, these results suggest that muscarinic agonists directly affected the proliferative ability of pancreatic β-cells through IRS-2.
Phosphorylation of Akt and protein level of cyclin D2 are increased in bethanechol-treated mouse islets.
To assess the mechanisms involved in muscarinic agonist-mediated β-cell proliferation, intracellular signalling was investigated in mouse islets. Following oral administration of bethanechol (1 µg/g) for 1 week in WT and IRS-2 −/− mice, islets were isolated and the phosphorylation of Akt was analysed by western blotting. The phosphorylation of Akt increased significantly in response to bethanechol in the WT mice, but not in the IRS-2 −/− mice (Fig. 5A ). The protein level of cyclin D2 also increased in response to bethanechol in the Experiments were performed in 8-to 10-week-old wild-type (WT) mice and insulin-receptor substrate 2 (IRS-2) −/− mice in standard chow diet-fed condition. (A) Plasma glucose levels during the oral glucose tolerance test (OGTT) following administration of bethanechol (Bch; 2 µg/g body weight). Bch was administered subcutaneously 15 min prior to oral glucose loading (1.5 mg/g body weight) in WT mice (left; n = 10) and IRS-2 −/− mice (right; n = 11). (B) Serum insulin levels during the OGTT following administration of Bch (2 µg/g) in WT mice (left; n = 10) and IRS-2 −/− mice (right; n = 10). (C) Plasma glucose levels during the insulin tolerance test following administration of Bch (2 µg/g). Bch was administered subcutaneously 15 min prior to insulin injection in WT mice (left; n = 6) and IRS-2 −/− mice (right; n = 4). The data represent the mean ± standard error of the mean (SEM); *P < 0.05 vs. control. Body Weight (g)
Week www.nature.com/scientificreports www.nature.com/scientificreports/ WT mice, but not in the IRS-2 −/− mice (Fig. 5B ). Bethanechol did not alter the protein levels of transcription factors FoxO1, FoxM1 or PDX1 (Fig. 5C ). These results suggest that the IRS-2/Akt/cyclin D2 pathway mediated bethanechol-induced β-cell proliferation. 
GLP-1 is released in bethanechol-treated mice and its antagonist inhibits the bethanecholinduced increase in β-cell mass.
To analyse the indirect effects of bethanechol, we focused on glucagon-like peptide-1 (GLP-1). The secretion of GLP-1 was measured 15 min following the subcutaneous administration of bethanechol (2 µg/g). GLP-1 secretion increased significantly in the bethanechol-treated WT mice, but there was no significant change in the secretion of GLP-1 in bethanechol-treated IRS-2 −/− mice (Fig. 6A ). www.nature.com/scientificreports www.nature.com/scientificreports/ To investigate the role of GLP-1, the mice were pretreated with the GLP-1 antagonist exendin 9-39 (30 pmol/g, intraperitoneally), 15 min prior to oral administration of bethanechol. Bethanechol was added at 10 µg/g once a day and the β-cell mass was measured 2 weeks following the start of administration. Bethanechol (10 µg/g) administration increased the β-cell mass significantly in the vehicle mice (control: 0.76 mg; bethanechol: 1.39 mg), whereas no significant increase in the β-cell mass was observed following agonist administration in the mice pretreated with exendin 9-39 (control: 0.97 mg; bethanechol: 1.15 mg) ( Fig. 6B ). However, exendin 9-39 did not completely suppress the increase in β-cell mass in the bethanechol-treated mice; there was still a bethanechol-induced marginal increase in the β-cell mass compared with that in the controls.
Discussion
In mice, islets are largely dominated by parasympathetic neurons 18 . Generally, in the pancreatic islets, the parasympathetic neurons promote insulin secretion and the sympathetic neurons inhibit insulin secretion [19] [20] [21] ; the brain and the vagal nervous system play an important role in pancreatic β-cell proliferarion. Because acetylcholine is the major neurotransmitter stored in vagal nerve endings, we aimed to elucidate the association between muscarinic receptor agonists and β-cell maintenance. Our results demonstrated that the muscarinic receptor agonist bethanechol improved glucose homeostasis in IRS-2 −/− and DIO mice, and increased the pancreatic β-cell proliferation. These proliferative effects were caused via simultaneous activation of the muscarinic receptor and the GLP-1 receptor signal (Fig. S2) .
Because vagal hyperactivity induces pancreatic β-cell proliferation, we hypothesised that chronic activation of muscarinic receptors in pancreatic β-cells might increase the β-cell mass. To test this hypothesis, we subjected mice to continuous, chronic administration of bethanechol, which significantly increased β-cell mass and BrdU incorporation ( Fig. 3C-E) . Furthermore, bethanechol-induced incorporation of BrdU was elevated significantly in islets isolated from the mice (Fig. 4F ) and MIN6 cells ( Fig. 4B ), suggesting that this muscarinic agonist directly affects the proliferative ability of pancreatic β-cells.
We confirmed that the M1 and M3 muscarinic receptors were expressed, and the M3 receptor was predominant in the murine β-cells (Fig. S3) . The β-cell mass increased in the transgenic mice with chronic activation of the Gq-coupled designer receptor which was created based on the M3 muscarinic receptor 6 , and mice treated with scopolamine butylbromide (a cholinergic antagonist) during lactation show lowered expression of the M3 receptor and decreased β-cell mass 22 . These findings suggest that the Gq-signalling of the M3 receptor was responsible for the β-cell mass expansion. However, a previous investigation on the effect of continuous stimulation of the β-cell M3 receptor on the β-cell mass and replication in transgenic mice demonstrated that it did not have a significant effect on the increase in the β-cell mass 4 . Pancreatic β-cell-specific knockout mice for the M3 muscarinic receptor do not exhibit obvious differences in the β-cell mass and cell size compared with WT mice 23 . Therefore, the direct effect of bethanechol on β-cell proliferation could not be caused by the M3 receptor signal alone. Because bethanechol activates all muscarinic receptor subtypes, activation of other muscarinic Gq receptor (e.g. M1) in the β-cell is also needed in bethanechol-induced β-cell proliferation.
It is well recognised that insulin signal molecules are important in the regulation of β-cell proliferation and mass expansion. Previous reports have suggested that IRS-2 and Akt proteins play a dominant role in regulating β-cell proliferation and maintaining β-cell mass [13] [14] [15] 24 . Akt1 increases the levels of cyclins D1 and D2, and the cyclin/CDK4/Akt complex is responsible for β-cell proliferation 25 . Gq-coupled receptor-signalling also increases β-cell mass through IRS-2/Akt pathway 6 . To identify the mechanisms of bethanechol-induced β-cell proliferation, we examined the role of insulin signal molecules. Bethanechol did not increase the β-cell mass in the IRS-2 −/− mice (Fig. 3C,E) , and it phosphorylated Akt protein and increased the protein levels of cyclin D2 in an IRS-2-dependent manner (Fig. 5 ). Our findings suggest that the bethanechol-induced β-cell proliferation was mediated by the IRS-2/Akt/cyclin D2 pathway. Although ERK1 and ERK2 are reported to be upstream of the function of IRS-2 in the Gq-coupled receptor pathway 6 , the MEK inhibitor did not inhibit the bethanechol-induced incorporation of BrdU in MIN6 cells (Fig. 4E) . The muscarinic agonist-induced β-cell proliferation might occur independently of ERK. A recent report indicated that co-stimulation of carbachol and PACAP promotes β-cell proliferation via FoxM1 in isolated islets 7 . Whereas we demonstrated that carbachol or bethanechol alone could increase BrdU uptake in islets or MIN6 cells (Fig. 4A,B,F) , bethanechol administration did not affect the protein levels of FoxM1 (Fig. 5) , and it did not lead to translocation of FoxM1 to the nucleus in murine islets (Fig. S4) . It is possible that bethanechol regulates the activity of FoxM1 rather than changing its protein level or localisation.
Besides the direct effects of bethanechol to the β-cell, the indirect mechanisms may also be involved in this bethanechol-induced β-cell proliferation in vivo. Bethanechol might increase the secretion of other hormones involved in the regulation of β-cell mass, which include GLP-1, insulin-like growth factors, growth hormone, hepatocyte growth factor, parathyroid hormone-related protein, the epidermal growth factor ligand family and lactogens. It is reported that β-cell proliferation requires Gs-signalling (PACAP receptor), in addition to Gq-signalling (M3 muscarinic receptor) 7 . Muscarinic receptor subtypes M1, M2 and M3 are expressed in the distal intestine 26, 27 and our findings showed that bethanechol enhanced the release of GLP-1 (Fig. 6A) , which is known to increase β-cell mass and activate Gs-signalling 16, 17 . The GLP-1 antagonist partially suppressed the increase in β-cell mass in the bethanechol-treated mice (Fig. 6B) . These results suggest that the GLP-1 receptor pathway is a factor in the muscarinic receptor-independent pathway. Therefore, the effects of the vagal nerve or bethanechol in pancreatic β cells may be exerted through the Gq-and Gs-signalling pathways (Fig. S2) .
Moreover, the indirect effects of bethanecol also affect the enhancement of insulin release. We indicated that the subcutaneous administration of bethanechol increased insulin release in the IRS-2 −/− mice more than that in the WT mice (Fig. 1B) , resulting in improved glucose tolerance in the IRS-2 −/− mice relative to the wild-type mice (Fig. 1A) . However, the glucose-stimulated secretion of insulin was similar in the islets of the IRS-2 −/− and WT mice (Fig. S5 ). Other unknown endogenous secretory proteins are associated with the enhancement of www.nature.com/scientificreports www.nature.com/scientificreports/ insulin release in the IRS-2 −/− mice. To identify these secretory factors in the IRS-2 −/− mice, we performed mass spectrometry-based proteomics analyses of plasma obtained from the control or IRS-2 −/− mice; these experiments remain under investigation.
In conclusion, we demonstrated the beneficial effects of bethanechol on glucose homeostasis and pancreatic β-cell maintenance. The administration of bethanechol improved glucose homeostasis, and it directly or indirectly stimulated β-cell proliferation. The GLP-1 receptor pathway may be indirectly associated with β-cell proliferation. Therefore, muscarinic agonists and their downstream molecules could be potential targets for novel diabetic therapies.
Methods
Animals and animal care. The C57BL/6J WT mice were obtained from CLEA Japan. We backcrossed IRS-2 −/− mice 28 with C57BL/6J mice more than 10 times. All experiments were performed using male mice maintained on a standard chow diet. The chronic effects of bethanechol were investigated in IRS-2 −/− mice and C57BL/6 J mice. Bethanechol was administered continuously (30 µg/mL in drinking water) or once-daily (1 µg/g given orally) in the IRS-2 −/− mice and WT mice. In the exendin 9-39 experiment, 30 pmol/g exendin 9-39 29 was administered intraperitoneally 15 min prior to bethanechol 10 µg/g administration orally in C57BL/6J mice for 2 weeks. In the experiment involving DIO mice, 7-week-old mice were fed a HFD. All animal procedures were performed in accordance with the institutional animal care guidelines and guidelines of the Animal Care Committee of Yokohama City University. The protocol was approved by the Yokohama City University Institutional Animal Care and Use Committee (permit no. F-A-18-020). The animals were housed in rooms maintained at a constant room temperature (25 °C) and on a 12-h light (from 07:00 AM onwards) and 12-h dark (from 7:00 PM onwards) cycle 30 .
Glucose tolerance and insulin tolerance tests. The plasma glucose levels and blood insulin levels were determined using GlutestNeoSuper (Sanwa Chemical Co.,) and an insulin kit (Morinaga), respectively. All mice were fasted for 18-22 hours prior to the oral glucose tolerance test followed by oral administration of glucose (1.5 mg/g body weight). An insulin tolerance test was performed by the intraperitoneal injection of mice with human insulin (0.75 mU/g body weight) 31 .
GLP-1 measurement. All mice were denied access to food for 18-22 h prior to subcutaneous administration of bethanechol (2 µg/g body weight). The active GLP-1 levels were measured 15 min after bethanechol administration using a GLP-1(Active) ELISA kit (Shibayagi). Blood was drawn into a syringe containing aprotinin (final concentration, 500 kIU/mL; Wako Pure Chemical Industries, Ltd.) as a dipeptidyl peptidase-IV inhibitor.
Histologic analysis. Mice were intraperitoneally injected with BrdU (100 µg/g; Nacalai Tesque, Inc) for 3 days and sacrificed. Three pancreatic tissue sections (100 µm apart) from each animal were prepared by fixation and paraffin-embedding. The sections were immunostained with antibodies to insulin, muscarinic acetylcholine receptor M1 (Santa Cruz), BrdU (Dako), and muscarinic acetylcholine receptor M3 (Bioss). Biotinylated secondary antibodies, a Vectastain elite ABC kit and a diaminobenzidine substrate kit (Vector) were used to examine the sections under bright-field microscopy to determine the β-cell mass. Alexa Fluor 488-and 555-conjugated secondary antibodies (Invitrogen) were used for fluorescence microscopy analysis. All images were captured using a BZ-9000 microscope (Keyence). The percentage area of the pancreatic tissues occupied by β cells was calculated using BIOREVO software (Keyence) 31 . In the BrdU staining experiment, 22-78 islets in each mouse were analysed to assess the frequency of BrdU-positive cells among the insulin-positive cells.
Cell culture and treatment. MIN6 cells (kindly provided by Professor Jun-ichi Miyazaki, Division of Stem
Cell Regulation Research, Osaka University, Graduate School of Medicine, Osaka, Japan) were used between passages 25 and 40 at ∼80% confluence. The MIN6 cells were grown in Dulbecco's modified Eagle medium (DMEM), containing 25 mM glucose supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS), and equilibrated in 5% CO 2 and 95% air at 37 °C 32 . Prior to the experiments, the medium was removed and the cells were washed twice with phosphate-buffered saline. Complete details of each treatment are provided in the corresponding figure legend.
BrdU incorporation in islets and MIN6 cells. Islets were isolated from 8-week-old mice using a method described previously 31 . The isolated islets were cultured in RPMI 1640 medium (Wako Pure Chemical Industries) containing 5.6 mM glucose supplemented with 1% FBS. Following incubation of the islets for 24 h in medium containing 1 mM bethanechol, 0.5 mM carbachol and BrdU, BrdU incorporation was measured with a BrdU cell proliferation assay (Calbiochem) in accordance with the manufacturer's protocol.
BrdU incorporation was also investigated in the MIN6 pancreatic β-cell line using the FITC-BrdU Flow kit (BD Pharmingen) in accordance with the manufacturer's protocol. Cells were cultured with serum-free DMEM containing 5.5 mM glucose for 24 h prior to stimulation. Cells were stimulated with muscarinic agonists for 24 h in the same medium, followed by the addition of BrdU. The cells were fixed 20 h later, stained with FITC-BrdU antibodies, and 20,000 cells were analysed by flow cytometry (FACS Canto II, BD Biosciences). The proportion of BrdU-positive cells was calculated using FACS DIVA software (BD Biosciences).
Immunoblotting. For immunoblotting, >100 isolated islets were lysed in ice-cold radioimmunoprecipitation buffer containing a complete protease inhibitor cocktail (Roche Diagnostics). The lysed islets were subjected to centrifugation and the extracts were subjected to immunoblotting with antibodies to the following proteins: Akt, phospho-Akt, forkhead transcription factor (FoxO1) (Cell Signalling Technology); cyclin D2, forkhead box
